Viewing nowCombinationJanugreen Duo Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.

MFDS item code 202200912 · Approved 2022.03.02 · Insurance code 650304380
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help patients with Type 2 diabetes manage their blood sugar levels. It can be used alone or in combination with other diabetes medications for those who find it difficult to control blood sugar levels while following a diet and exercise program. For instance, this medication may be administered if prior diabetes medications have not been used or if blood sugar control is insufficient with monotherapy using metformin or sitagliptin. Additionally, it can be used in conjunction with metformin when combination therapy with sulfonylureas or thiazolidinediones fails to yield adequate results. It is also used alongside insulin when blood sugar control is difficult with the combination of insulin and metformin. Ultimately, this medication assists in improving blood sugar control under a variety of diabetes treatment conditions.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for patients who do not achieve adequate glycemic control with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This medication contains sitagliptin and metformin, which are used for diabetes treatment. First, sitagliptin may rarely cause serious allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, the medication must be discontinued immediately and a doctor should be consulted. Also, pancreatitis, which is inflammation of the pancreas, may occur, so if symptoms like abdominal pain, vomiting, or loss of appetite arise, medical personnel should be notified immediately. Metformin may cause a rare complication known as lactic acidosis, which can manifest as muscle pain, difficulty breathing, fatigue, and abdominal pain; in this case, medication use should be stopped immediately and hospitalization is necessary. This medication should not be administered to patients with moderate to severe renal impairment, acute infections, heart failure, or acute myocardial infarction. Additionally, patients scheduled for radiographic contrast studies should stop taking this medication 48 hours prior to the test and resume only after confirming normal renal function. It is not to be used in pregnant or breastfeeding women, or in individuals under 18 years of age. In elderly patients, renal function may decline; thus, dosage adjustments and regular renal function tests are necessary. During treatment with this medication, excessive alcohol consumption should be avoided, and care should be taken for the risk of hypoglycemia during irregular meals or strenuous exercise. Moreover, when combined with other hypoglycemic agents, there may be hypoglycemic symptoms, so attention to symptoms and dosage adjustments may be necessary if needed. Prior to surgery, this medication should be temporarily discontinued and resumed only after confirming normal renal function post-surgery. If severe joint pain or skin vesicles occur during treatment, the doctor should be informed immediately, and medication discontinuation may be necessary in such cases. Regular blood tests and renal function tests are crucial for early detection and management of adverse reactions.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air, and it is advisable to keep it at room temperature between 1 to 30 degrees Celsius. By storing it this way, the drug's efficacy can be maintained and degradation can be prevented.
Pink oval film-coated tablets
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.